8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (May 5, 2015)

Filed May 5, 2015For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the successful closing of a significant debt offering on May 5, 2015. The company issued €575,000,000 in aggregate principal amount of 1.000% notes due in 2025 and an equal amount of 1.750% notes due in 2035. This offering was executed under an Underwriting Agreement dated April 29, 2015, with major financial institutions acting as joint book-running managers. The issuance of these notes, registered under the Securities Act of 1933, indicates the company's strategy to access capital markets for its funding needs. Investors can view the detailed terms of the notes and the associated agreements, including the Underwriting Agreement and the Eighth Supplemental Indenture, which are filed as exhibits to this report. This action provides transparency regarding BMY's financial structure and its commitment to securing long-term financing.

Key Highlights

  • 1BMY successfully closed a debt offering on May 5, 2015.
  • 2The company issued €575 million in 1.000% notes due 2025.
  • 3An additional €575 million in 1.750% notes due 2035 were also issued.
  • 4The total principal amount of notes issued is €1.15 billion.
  • 5The offering was conducted under an Underwriting Agreement dated April 29, 2015.
  • 6The notes are governed by an Indenture and an Eighth Supplemental Indenture.
  • 7The offering was registered under the Securities Act of 1933.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the closing of Bristol-Myers Squibb's debt offering, where they issued two series of notes totaling €1.15 billion.

The company issued €575 million of notes with a 1.000% interest rate due in 2025, and another €575 million of notes with a 1.750% interest rate due in 2035.

Detailed information about the debt offering, including the Underwriting Agreement and the Supplemental Indenture, are filed as exhibits to this 8-K report and are available for review by investors.

This filing pertains to the issuance of new debt. While it increases the company's overall debt obligations, further analysis would be needed to understand its impact on existing debt covenants or financial ratios. The details of the Indenture and Supplemental Indenture would provide specific terms.